CD163 and ductal breast carcinoma in situ: There were not statistically significant differences in the level of CD163 + cells between 30 primary DCIS patients with further recurrence and 11 primary DCIS patients without failure (median score 1% vs. 1% of stromal immune cells, respectively, p = 0.942).